Research Topics
Genomes and Genes | David Z ChangSummaryAffiliation: US Oncology Country: USA Publications
| Collaborators
|
Detail Information
Publications
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapyDavid Z Chang
Departments of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
J Hematol Oncol 2:18. 2009..It should now become a standard practice that any patients being considered for EGFR targeted therapies have their tumors tested for KRAS status and only those with wild-type KRAS being offered such therapies...
Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progressionDavid Z Chang
Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
J Hematol Oncol 5:15. 2012..abstract:..
Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinomaDavid Z Chang
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 17:7015-23. 2011..Inflammatory cells, particularly mast cells, have been shown to play key roles in some cancers. We carried out this study to test the hypothesis that mast cells in the tumor microenvironment are essential for PDAC tumorigenesis...
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer
Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 26:5344-51. 2008..The secondary goal of the study was to identify the clinical predictors of pathologic response...
Effects of base excision repair gene polymorphisms on pancreatic cancer survivalDonghui Li
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1402, USA
Int J Cancer 120:1748-54. 2007..These observations need to be confirmed in a larger study of homogenous patient population...
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastasesDario Ribero
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 110:2761-7. 2007..The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology...
Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathwayScott Kopetz
Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
J Clin Oncol 26:2000-5. 2008..It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer...
Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancerLi Jiao
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 109:840-8. 2007..The authors hypothesized that genetic variants of glutathione S-transferase (GST) affect detoxification of carcinogens and anticancer agents in the human pancreas and, thus, the risk and survival of pancreatic cancer...
Ras activity levels control the development of pancreatic diseasesBaoan Ji
Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Gastroenterology 137:1072-82, 1082.e1-6. 2009..However, we hypothesized that acinar cells would develop PDAC in the presence of Ras activity levels mimicking those of human tumor cells...
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse modelsKuichun Zhu
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
Vaccine 25:7955-61. 2007..We conclude that survivin DNA vaccine generated specific antitumor effects with increased lymphocyte infiltration at the tumor sites...
Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascitesSatoshi Ishiyama
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Oncol 30:889-98. 2007..Immunotherapy with tumor antigens from Notch and Numb should be important for treatment of cancer patients...
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activityZhiliang Jia
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 70:1111-9. 2010....
Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cellsNaotake Tsuda
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 67:8378-87. 2007..Elucidation of the composition of ISMMC and identification of adducts formed by Taxol should be important for developing molecular cancer vaccines...
Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individualsChantale Bernatchez
Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, United States
Vaccine 29:3021-30. 2011..Thus, vaccinating with both the 10-mer and 9-mer peptides would be required to immunize a maximum number of individuals in the HLA-A0201(+) population and could lead to more consistent T-cell responses against this region of Survivin...
Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysisYufeng Li
Graduate School of Biomedical Science, UT Health Science Center at Houston, Houston, TX 77030, USA
Int J Mol Med 18:1127-39. 2006..Because most tumors are infiltrated by lymphocytes, our studies indicate a novel approach to identify 'systemic biological responses' of T cells, which could determine the design, and optimization of effective tumor vaccines...
HLA-A0201 positive pancreatic cell lines: new findings and discrepanciesKuichun Zhu
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Immunol Immunother 56:719-24. 2007..Our findings were verified with two different sequence-based typing methods, antibody staining followed by flow cytometry analysis, and functional analysis using an HLA-A0201-restricted peptide-specific T cell response...
Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cellsNaotake Tsuda
Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4095, USA
Clin Cancer Res 12:6557-64. 2006..CONCLUSIONS: Gli-1 miRNAs should significantly add to the general understanding of the mechanisms of metastasis and contribute toward the design of better treatments for epithelial cancers...
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II studyJames C Yao
Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 26:4311-8. 2008..Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors...
Second-line chemotherapy use in metastatic colon cancer varies by disease responsivenessSeth Politano
University of Texas Health Science Center, Houston, TX, USA
Clin Colorectal Cancer 7:55-9. 2008..However, it is unclear which patient, disease, and treatment characteristics are associated with the utilization of a second-line regimen...
Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survivalYun Shin Chun
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
J Gastrointest Surg 11:1498-504; discussion 1504-5. 2007..The aim of this study was to compare the outcome of patients with CLM treated with preoperative chemotherapy followed by one- or two-stage hepatectomy...
The current status of vaccine development in colorectal cancerDavid Z Chang
GI Medical Oncology and Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Adv Hematol Oncol 5:109-11, 136. 2007
Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survivalDonghui Li
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
Cancer Res 66:3323-30. 2006..These observations suggest that polymorphisms of genes involved in the repair of DNA double-strand breaks significantly affect the clinical outcome of patients with pancreatic cancer...
Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergyPrakash Thapa
Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77054, USA
Vaccine 27:3484-8. 2009..Hence, nanoparticle formulated alpha-galactosylceramide is an attractive immunomodulator for immunotherapy and vaccine development. Future studies will be focused on its application as adjuvant for protein and/or peptide antigens...
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOXDavid Z Chang
M. D. Anderson Cancer Center, University of Texas, TX, USA
Clin Adv Hematol Oncol 3:400-4. 2005
